InVitae (NYSE: NVTA) and Vermillion (NASDAQ:VRML) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.
This is a summary of current ratings and price targets for InVitae and Vermillion, as reported by MarketBeat.
||Strong Buy Ratings
InVitae presently has a consensus price target of $12.75, indicating a potential upside of 95.55%. Vermillion has a consensus price target of $2.25, indicating a potential upside of 55.17%. Given InVitae’s higher probable upside, research analysts clearly believe InVitae is more favorable than Vermillion.
Earnings & Valuation
This table compares InVitae and Vermillion’s revenue, earnings per share and valuation.
||Earnings Per Share
Vermillion has lower revenue, but higher earnings than InVitae. Vermillion is trading at a lower price-to-earnings ratio than InVitae, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
64.9% of InVitae shares are owned by institutional investors. Comparatively, 34.9% of Vermillion shares are owned by institutional investors. 9.9% of InVitae shares are owned by insiders. Comparatively, 3.7% of Vermillion shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares InVitae and Vermillion’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
InVitae beats Vermillion on 9 of the 12 factors compared between the two stocks.
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company’s products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.
Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.